Last October, Altasciences expanded into the United States with the opening of Algorithme Pharma USA, in Fargo, North Dakota. Today, we are pleased to announce that our first studies were initiated and completed in January, just 91 days from the US contract being signed, and despite the holiday hustle.
In French only - Algorithme Pharma s’est distinguée lors des Grands Prix québécois de la qualité. Le ministre de l'Économie, de l'Innovation et des Exportations, Jacques Daoust, a procédé le 13 novembre à la remise des Grands Prix québécois de la qualité, en compagnie du président du conseil d'administration du Mouvement québécois de la qualité, Roch L. Dubé.
Altasciences is pleased to announce the opening of Algorithme Pharma USA, further expanding the Company’s North American footprint and ability to provide comprehensive Bioequivalence and Phase I/IIa clinical drug development capabilities in the United States.
During a recent drug development symposium held at the NEOMED Institute in Montreal, Dr. Marc Lefebvre, Vice-President Scientific & Regulatory Affairs, Algorithme Pharma Inc., addressed life science executives on developing efficient First-In-Human (FIH) clinical trials to help reduce costs and shorten the timeline for approval of new drugs.
Industry Recognizes Algorithme Pharma as Preeminent CRO that Surpasses Sponsor Expectations and Provides Greater Value
Algorithme Pharma, a full service early stage clinical research organization, has been presented with the Innovation, Productivity, Quality and Regulatory CRO leadership awards by Life Science Leader Magazine.